See more : BCE Inc. (BCE-PA.TO) Income Statement Analysis – Financial Results
Complete financial analysis of Galera Therapeutics, Inc. (GRTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Galera Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- UIE Plc (UIE.CO) Income Statement Analysis – Financial Results
- Transglobe Foods Limited (TRANSFD.BO) Income Statement Analysis – Financial Results
- 2U, Inc. (TWOU) Income Statement Analysis – Financial Results
- Rossell India Limited (ROSSELLIND.NS) Income Statement Analysis – Financial Results
- Zhe Jiang Headman Machinery Co.,Ltd. (688577.SS) Income Statement Analysis – Financial Results
Galera Therapeutics, Inc. (GRTX)
About Galera Therapeutics, Inc.
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 259.00K | 114.00K | 778.00K | 368.00K | 267.00K | 127.00K | 84.00K |
| Gross Profit | -259.00K | -114.00K | -778.00K | -368.00K | -267.00K | -127.00K | -84.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 24.12M | 31.01M | 52.42M | 54.85M | 42.33M | 18.66M | 20.59M |
| General & Administrative | 22.84M | 20.21M | 20.95M | 15.71M | 8.36M | 5.59M | 3.50M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 22.84M | 20.21M | 20.95M | 15.71M | 8.36M | 5.59M | 3.50M |
| Other Expenses | 0.00 | -11.07M | -7.17M | -3.68M | -1.25M | 0.00 | 0.00 |
| Operating Expenses | 46.95M | 51.23M | 73.37M | 70.55M | 50.69M | 24.26M | 24.09M |
| Cost & Expenses | 46.95M | 51.23M | 73.37M | 70.55M | 50.69M | 24.26M | 24.09M |
| Interest Income | 9.82M | 506.00K | 32.00K | 1.17M | 1.82M | 606.00K | 193.00K |
| Interest Expense | 0.00 | 11.57M | 7.19M | 4.88M | 3.03M | 220.00K | 0.00 |
| Depreciation & Amortization | 259.00K | 114.00K | 778.00K | 368.00K | 267.00K | 127.00K | 84.00K |
| EBITDA | -46.69M | -50.61M | -72.56M | -69.01M | -50.69M | -23.52M | -23.82M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -46.95M | -51.23M | -73.37M | -70.55M | -50.69M | -24.26M | -24.09M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -12.13M | -11.07M | -7.17M | -3.68M | -1.25M | 356.00K | 189.00K |
| Income Before Tax | -59.08M | -62.29M | -80.53M | -74.23M | -51.94M | -23.90M | -23.91M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -70.00K | 7.19M | -16.00K | -9.00K | -223.00K | -360.00K |
| Net Income | -59.08M | -62.22M | -87.73M | -74.22M | -51.93M | -23.68M | -23.55M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.33 | -2.30 | -3.40 | -2.98 | -2.09 | -1.22 | -1.55 |
| EPS Diluted | -1.33 | -2.30 | -3.40 | -2.98 | -2.09 | -1.22 | -1.55 |
| Weighted Avg Shares Out | 44.55M | 27.09M | 25.79M | 24.87M | 24.81M | 19.36M | 15.22M |
| Weighted Avg Shares Out (Dil) | 44.55M | 27.09M | 25.79M | 24.87M | 24.81M | 19.36M | 15.22M |
Galera to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
Galera Therapeutics' Rucosopasem Shows Early Anti-Cancer Activity, Pulmonary Function Preservation
Galera to Present at Jefferies Healthcare Conference
Is Galera Therapeutics Stock A Buy, Sell, Or Hold? Several Catalysts To Watch In 2022
Galera to Present at H.C. Wainwright BioConnect Conference
Top Penny Stocks to Buy in 2022? Check These 3 Out Right Now
Trending Penny Stocks to Buy Today? 3 For Your Watchlist
Galera Therapeutics Stock (GRTX): Why The Price Surged Today
Galera Therapeutics Shares Surge As Citi Bumps Up Price Target To $20
Check These Penny Stocks Out For Your Watchlist As the Market Dips
Source: https://incomestatements.info
Category: Stock Reports